Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHT101 in Recurrent or Progressive Malignant Primary Brain Tumors
NCT07496073Phase 1Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of CHT101 in malignant brain tumor, sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Safety and Tolerability at 2 years. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
CHT101
03
Conditions
malignant brain tumor
Beyond the preview
Go deeper on NCT07496073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07496073.